27th Dec 2006 10:00
Tepnel Life Sciences PLC27 December 2006 Tepnel Life Sciences plc ('Tepnel' or 'the Company') Block Listing Manchester, U.K, 27 December 2006 Tepnel Life Sciences PLC (AIM: TED), theUK-based international Molecular Diagnostics and Research Products & Servicesgroup, confirms that under the Equity Line of Credit facility block listingapplication for the admission to trading of up to 6,000,000 ordinary shares of1p each ("Ordinary Shares") announced on 1 March 2004, the Company issued andallotted 4,765,070 Ordinary Shares to Cornell Capital Partners Offshore L.P. inthe financial year ended 31 December 2004. The balance of 1,234,930 OrdinaryShares have not been issued under the Equity Line of Credit facility blocklisting application. -End- For Further Information: Tepnel Life Sciences plcBen Matzilevich, CEO0161 946 2200 Seymour Pierce LimitedMark Percy0207 107 8000 Notes to Editors About Tepnel Life Sciences plcTepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two main divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. TLS provides testkits, reagents and services to two highly synergistic markets, these beingMolecular Diagnostics and Biomedical Research. The company's strategy has beento identify high growth niche opportunities within these multi-billion poundmarkets. TLS focuses on these niche opportunities with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L